Impact of Travel Distance on Radiation Treatment Modality for Central Nervous System Disease

Shearwood McClelland III1,2, Timur Mitin2, Jerry J. Jaboin2, Jeremy N. Ciporen3

1Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, Indiana, United States
2Department of Radiation Medicine, Oregon Health and Science University, Portland, Oregon, United States
3Department of Neurological Surgery, Oregon Health and Science University, Portland, Oregon, United States

Address for correspondence Shearwood McClelland III, MD, Department of Radiation Medicine, Indiana University School of Medicine, 535 Barnhill Drive, RT 041, Indianapolis, IN 46202, United States (e-mail: dhwood@post.harvard.edu).

Abstract

Background Stereotactic body radiation therapy (SBRT) has emerged as a popular alternative to conventional radiation therapy (RT) over the past 15 years. Unfortunately, the impact of patient distance from radiation treatment centers and utilization of SBRT versus conventional RT has been sparsely investigated. This report represents the first analysis of the impact of patient distance on radiation treatment modality for central nervous system (CNS) disease.

Materials and Methods Since the inception of our RADIation oncology And NeuroSurgery (RADIANS) multidisciplinary clinic at a community hospital in 2016, 27 patients have received either SBRT or conventional RT as their sole radiation treatment modality for CNS disease. Twenty-four (88.9%) presented with metastatic disease. Fisher’s exact test evaluated the relationship between patient residence from treatment (in miles) and radiation treatment modality received.

Results Mean patient distance from our RADIANS clinic was 50.6 miles (median = 15.3). Twenty-one patients (77.8%) received SBRT; the remaining six received conventional RT. Mean patient distance from SBRT was 63.6 miles, and mean patient distance for conventional RT was 5.1 miles; this finding was statistically significant (p = 0.0433; 95% confidence interval = 1.9–115.1).

Conclusion Our findings indicate that patients with CNS disease who receive SBRT over conventional RT are statistically more likely to reside further from treatment centers. This is similar to findings of national studies comparing proton versus photon treatment for pediatric solid malignancies. The results from our work have implications for neuro-oncology treatment and the development of community hospital-based clinic models similar to RADIANS in the future.

Introduction

The increasing popularity of stereotactic body radiation therapy (SBRT) as an alternative to conventional radiation therapy (RT) has permeated oncology over the past 15 years.1-3 Unfortunately, the impact of patient distance from radiation treatment centers and utilization of SBRT versus conventional RT has been sparsely investigated; a recent report investigating localized prostate cancer found that patients residing more than 25 miles from treatment centers were significantly more likely to receive SBRT than conventional fractionation.3 For patients receiving treatment in a community hospital setting, this distance may play a significant role in treatment; many patients reside more than 50 miles away from their nearest treatment center, with some residing more than 250 miles away. This report represents the first

DOI https://doi.org/10.1055/s-0039-3399431
ISSN 0976-3147.
©2019 Association for Helping Neurosurgical Sick People
analysis of the impact of patient distance on radiation treatment modality for central nervous system (CNS) disease.

Materials and Methods
Since the inception of our RADIation oncology And Neuro-Surgery (RADIANS) multidisciplinary clinic at a community hospital in 2016, 27 patients have received either SBRT or conventional RT as their sole radiation treatment modality for CNS disease; the radiation treatment center is located in the same building as the clinic. Twenty-four of these patients (88.9%) presented with metastatic disease of the brain or spine. Of these 24 patients, 12 had brain metastases, 11 had spine metastases, and 1 had both brain and spine metastases. Statistical analyses were performed using t-tests to evaluate the relationship between patient residence from treatment (in miles), and radiation treatment modality received, with statistical significance assigned at $p < 0.05$ (GraphPad Software, San Diego, California, United States).

Results
Mean patient age was 64.4 (median = 67). Mean patient distance from our RADIANS clinic was 50.6 miles (median = 15.3). Fifteen patients resided < 25 miles away from clinic; eight were 51 to 100 miles away, and two were 200+ miles away from treatment. Twenty-one of the 27 patients received SBRT (77.8%); the remaining six received conventional RT. Mean patient distance from SBRT was 63.6 miles (standard error of mean [SEM] = 14.5), while for conventional RT mean patient distance from treatment was 5.1 miles (SEM = 1.9); this finding was statistically significant ($p = 0.0433$; 95% confidence interval = 1.9–115.1).

Conclusion
As recently reported for localized prostate cancer, our findings indicate that patients with CNS disease who receive SBRT over conventional RT are statistically more likely to reside further from treatment centers. This is similar to findings of national studies comparing proton versus photon treatment for pediatric solid malignancies, where patients receiving proton therapy were significantly more likely to travel > 200 miles to do so. Unlike for prostate and breast cancer, for CNS disease there is not Level I evidence establishing hypofractionation as equivalent to conventional RT; it is more likely that the paucity of SBRT access in the treatment of brain/spine disease is the catalyst for our distance-related findings. The results from our work have implications for neuro-oncology treatment and the development of community hospital-based clinic models similar to RADIANS in the future. Further multi-center analyses will be warranted to determine whether the findings from this small retrospective study persist after undergoing more rigorous investigation.

Funding
T.M. received research funding from Novocure.

Conflict of Interest
None declared.

References